Stoke Therapeutics, Inc. (STOK) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	27.6M	184.4M	36.6M	8.8M	12.4M
Cost of Revenue	4.2M	—	—	—	—
Gross Profit	23.4M	184.4M	36.6M	8.8M	12.4M
Operating Expenses
R&D Expense	167.3M	137.9M	89.1M	82.2M	77.8M
SG&A Expense	80.5M	67.1M	48.8M	41.3M	38.9M
General & Admin Expense	—	67.1M	48.8M	41.3M	38.9M
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	(1.0M)	—	—	—	—
Total Operating Expenses	246.7M	205.0M	137.9M	123.6M	116.8M
Cost and Expenses	251.0M	205.0M	137.9M	123.6M	116.8M
Operating Income (EBIT)	(223.4M)	(20.6M)	(101.4M)	(114.8M)	(104.4M)
Non-Operating
Interest Income	14.0M	13.8M	12.6M	9.9M	3.1M
Interest Expense	46.0K	9.0K	—	—	—
Net Interest Income	14.0M	13.8M	12.6M	9.9M	3.1M
Other Non-Op Income/Expense	14.2M	13.7M	12.4M	10.1M	3.3M
Non-Operating Income (excl Interest)	(13.8M)	(13.7M)	(12.4M)	(10.1M)	(3.3M)
EBT (Pre-Tax Income)	(209.2M)	(6.9M)	(89.0M)	(104.7M)	(101.1M)
Income Tax Expense	(1.3M)	—	—	—	—
Bottom Line
Net Income	(207.9M)	(6.9M)	(89.0M)	(104.7M)	(101.1M)
Earnings from Cont. Ops	(207.9M)	(6.9M)	(89.0M)	(104.7M)	(101.1M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(207.9M)	(6.9M)	(89.0M)	(104.7M)	(101.1M)
Per Share
Basic EPS	($3.36)	($0.12)	($1.65)	($2.38)	($2.60)
Diluted EPS	($3.36)	($0.12)	($1.65)	($2.38)	($2.60)
Revenue Per Share	$0.42	$3.11	$0.68	$0.20	$0.32
Shares
Basic Shares Outstanding	66.0M	59.2M	54.0M	44.0M	38.9M
Diluted Shares Outstanding	66.0M	59.2M	54.0M	44.0M	38.9M
Profitability Metrics
EBITDA	(205.4M)	(5.1M)	(86.8M)	(102.2M)	(99.5M)
D&A	4.2M	1.8M	2.2M	2.5M	1.5M
EBIT	(209.6M)	(6.9M)	(89.0M)	(104.7M)	(101.1M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026